News Releases

News Releases

May 18, 2022
PRINCETON, N.J. --(BUSINESS WIRE)--May 18, 2022-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will present at the following healthcare conferences: H.C.
May 16, 2022
-- Multi-Center Retrospective Study was Presented at the 2022 American Urological Association Annual Meeting in New Orleans -- NEW ORLEANS --(BUSINESS WIRE)--May 16, 2022-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to creating novel solutions that treat urothelial and specialty
Mar 29, 2022
--Multi-arm Phase 1 study will evaluate the safety, tolerability and establish the recommended Phase 2 dose of monotherapy and combination therapy to treat recurrent non-muscle invasive bladder cancer (NMIBC) --Study design utilizes Master Protocol to accelerate evaluation of combination therapies